Münster, Germany and Philadelphia, US—June 21, 2019 Innate Biologics™ has entered into a multi-year collaboration agreement with one of Germany’s leading scientific and research institutes with a focus on skin applications.
PHILADELPHIA, PA — September 23, 2019 —Innate Biologics™ has been granted patent protection for its novel E3 Ligase recombinant protein platform that targets inflammatory signaling pathways.
Philadelphia, PA — June 25, 2019 — Innate Biologics, LLC has entered into an exclusive license agreement with The Wistar Institute, an internationally recognized leader in biomedical research, to co-owned patent rights related to a unique anti-inflammatory protein platform resulting from a 2018 research collaboration between Innate Biologics and Wistar.
Innate Biologics, LLC enters into collaboration agreement with The Wistar Institute to develop anti-inflammatory protein platform. Collaboration focused on new approaches to target and treat inflammation at the molecular level.
